Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease
Michelle M. Gonzalez, … , Raul Urrutia, William A. Faubion Jr.
Michelle M. Gonzalez, … , Raul Urrutia, William A. Faubion Jr.
Published June 15, 2021
Citation Information: J Clin Invest. 2021;131(12):e140755. https://doi.org/10.1172/JCI140755.
View: Text | PDF
Research Article Autoimmunity Gastroenterology

BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease

  • Text
  • PDF
Abstract

FOXP3+ Tregs are expanded within the inflamed intestine of human Crohn’s disease, yet FOXP3-mediated gene repression within these cells is lost. The polycomb repressive complexes play a role in FOXP3 target gene regulation, but deeper mechanistic insight is incomplete. We have now specifically identified the polycomb-repressive complex 1 (PRC1) family member, BMI1 in the regulation of a proinflammatory enhancer network in both human and murine Tregs. Using human Tregs and lamina propria T cells, we inferred PRC1 to regulate Crohn’s associated gene networks through assays of chromatin accessibility. Conditional deletion of BMI1 in murine FOXP3+ cells led to systemic inflammation. BMI1-deficient Tregs beared a TH1/TH17-like phenotype as assessed by assays of genome wide transcription, chromatin accessibility and proteomic techniques. Finally, BMI1 mutant FOXP3+ cells did not suppress colitis in the adoptive transfer model of human inflammatory bowel disease. We propose that BMI1 plays an important role in enforcing Treg identity in vitro and in vivo. Loss of Treg identity via genetic or transient BMI1 depletion perturbs the epigenome and converts Tregs into Th1/Th17-like proinflammatory cells, a transition relevant to human Crohn’s disease associated CD4+ T cells.

Authors

Michelle M. Gonzalez, Adebowale O. Bamidele, Phyllis A. Svingen, Mary R. Sagstetter, Thomas C. Smyrk, Joseph M. Gaballa, Feda H. Hamdan, Robyn Laura Kosinsky, Hunter R. Gibbons, Zhifu Sun, Zhenqing Ye, Asha Nair, Guilherme P. Ramos, Manuel B. Braga Neto, Alexander Q. Wixom, Angela J. Mathison, Steven A. Johnsen, Raul Urrutia, William A. Faubion Jr.

×

Figure 2

The canonical PRC1 member BMI1 is uniquely expressed in murine lymphocytes.

Options: View larger image (or click on image) Download as PowerPoint
The canonical PRC1 member BMI1 is uniquely expressed in murine lymphocyt...
(A) Representative IB analysis of BMI1 and MEL18 protein expression in freshly isolated murine CD25++ Tregs. (B) Upregulation of BMI1 mRNA upon in vitro induction of murine Tregs from naive cells cultured under polarizing conditions with TGF-β1 and IL-2 for 5 days. (C) Representative PLA images demonstrate the interaction between BMI1 and RING1B (red dots) present in murine iTregs vs naive CD4+ T cells (7.8 ± 6.3 vs. 0.35 ± 0.45, P = 0.03, n = 4 mice per group). The units for PLA are an average of the number of dots (red dots) present within cells, representing BMI1-RING1B protein complexes. (D) Representative IB analysis depicts decreased protein expression of BMI1 and H2AK119ub expression in human T cell leukemic line (Jurkat E6 cells) upon pharmacologic treatment with the BMI1 inhibitor, PTC209. (E) IL2 expression in Jurkat cells upon pharmacologic inhibition of BMI1 with PTC209 measured by fluorescent activated cell sorting (FACS) and flow cytometric analysis. (F) Chromatin immunoprecipitation and quantitative PCR depicts a global loss of H2AK119 ubiquitination mark on the IL2 promoter in Jurkat cells in the presence of the BMI1 inhibitor, PTC209, respectively.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts